← Back to Search

Mind Wandering Intervention for Attention Deficit Disorder

N/A
Waitlist Available
Led By Paul T. Cirino, PhD
Research Sponsored by University of Houston
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
enrollment in schools where we have permission to conduct the study
Be younger than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up on 12 occasions interspersed during each of the math and reading learning sessions, on day 1 only.
Awards & highlights

Study Summary

This study assesses the impact of mind-wandering on reading and math.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~on 12 occasions interspersed during each of the math and reading learning sessions, on day 1 only.
This trial's timeline: 3 weeks for screening, Varies for treatment, and on 12 occasions interspersed during each of the math and reading learning sessions, on day 1 only. for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Investigator Developed Items Derived From Math Content Being Taught
Investigator Developed Items Derived From Reading Content Being Taught
Secondary outcome measures
Investigator Developed Probe-Caught Mind-Wandering

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: Mind Wandering InterventionExperimental Treatment1 Intervention
75% of participants will receive proactive and reactive mind-wandering information and redirection.
Group II: Mind Wandering ComparisonActive Control1 Intervention
25% of participants will receive only mind-wandering redirection, but only at random times.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
mind-wandering intervention
2022
N/A
~60

Find a Location

Who is running the clinical trial?

University of HoustonLead Sponsor
146 Previous Clinical Trials
47,484 Total Patients Enrolled
Paul T. Cirino, PhDPrincipal InvestigatorUniversity of Houston

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
~19 spots leftby Mar 2025